Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18998134 | 0.87 | KDM4E (0.49) | PDE10AKDM4ETDP1CYP19A1L3MBTL1 | |
| SCHEMBL31688060 | 0.87 | KDM4E (0.49) | PDE10AKDM4ETDP1CYP19A1L3MBTL1 | |
| SCHEMBL18997515 | 0.85 | NPC1 (0.47) | PDE10AKDM4ETDP1CYP19A1L3MBTL1 | |
| SCHEMBL20665754 | 0.84 | KDM4E (0.49) | PDE10AKDM4ETDP1CYP19A1L3MBTL1 | |
| SCHEMBL24128152 | 0.83 | PDE10A (0.41) | PDE10AKDM4ETDP1CYP19A1L3MBTL1 | |
| SCHEMBL20665711 | 0.82 | KDM4E (0.44) | PDE10AKDM4ETDP1CYP19A1L3MBTL1 | |
| SCHEMBL8145981 | 0.82 | L3MBTL1 (0.45) | PDE10AKDM4ETDP1L3MBTL1NPC1 | |
| SCHEMBL20665240 | 0.82 | MEN1 (0.46) | PDE10AKDM4ETDP1CYP19A1L3MBTL1 | |
| SCHEMBL24827580 | 0.82 | PDE10A (0.45) | PDE10AKDM4ETDP1CYP19A1L3MBTL1 | |
| SCHEMBL20665195 | 0.81 | PRKCI (0.42) | PDE10AKDM4ETDP1CYP19A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3642209-B1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | COLLINS MICHAEL R | 2007-10-25 | — | — | US | disclosed |
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | COLLINS MICHAEL R | 2007-10-25 | — | — | US | disclosed |
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | COLLINS MICHAEL R | 2007-10-25 | — | — | US | disclosed |
| EP-1805187-A1 | INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | Pfizer, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006043145-A1 | INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006043145-A1 | INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | PDE10A 1360/4885KDM4E 3392/4885TDP1 3252/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | PDE10A 2766/4885KDM4E 4215/4885TDP1 3901/4885 |
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | SERPINB1, CTSC, CTSV | PDE10A 3658/4885KDM4E 2302/4885TDP1 3612/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | PDE10A 1360/4885KDM4E 3392/4885TDP1 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.